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Abstract
Background—Since 1996, six new drugs have been introduced for the treatment of metastatic
colorectal cancer. While promising, these drugs are frequently given in the palliative, and are much
more expensive than older treatments. The objective of this study is to measure the cost implications
of treatment with sequential regimens that include chemotherapy and/or monoclonal antibodies.
Methods—A Markov model evaluated a hypothetical cohort of 1000 patients with newly diagnosed
metastatic colorectal cancer. Patients are treated with up to three lines of treatment prior to supportive
care and subsequent death. Data was obtained from published multicenter phase II and randomized
phase III clinical trials. Sensitivity analyses were conducted on the efficacy, toxicity and cost.
Results—Using drug costs alone, treatment including new chemotherapeutic agents increases
survival at an incremental cost effectiveness ratio (ICER) of $100,000/discounted life year (DLY).
Addition of monoclonal antibodies improves survival at an ICER of over $170,000/DLY. Results
are most sensitive to changes in the initial regimen. Even with significant improvements in clinical
characteristics (efficacy and toxicity), treatment with the most effective regimens still have an very
high ICERs
Conclusions—Treatment of metastatic colorectal cancer with the most effective regimens comes
at very high incremental costs. Cost effectiveness analyses should be a routine component of the
drug development process, so that physicians and patients are appropriately informed regarding the
value of new innovation.
Introduction
The treatment of metastatic colorectal cancer has changed dramatically in the last decade.
Introduced in the 1950's, 5 Fluorouracil (5FU) was the first drug available for treatment of
metastatic colorectal cancer. Overall survival remained at approximately one year, despite
biomodulation with leucovorin. Irinotecan was approved in 1996, followed by oxaliplatin in
2000. In 2004, the monoclonal antibodies cetuximab and bevacizumab were introduced for
treatment of metastatic colorectal cancer. Panitumumab gained approval in late 2006 for
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patients who had failed chemotherapy. With these new agents, there has been a paradigm shift
in the treatment of patients with metastatic colorectal cancer with a doubling of median survival
over 5FU alone and a potential for long term survival in a significant minority of patients.1
Unfortunately, the vast majority are not cured and each new drug offers only modest survival
benefits. Irinotecan increases median overall survival by 2.2 months when added to 5FU/LV.
2 Oxaliplatin, when given in combination with infusional 5FU (FOLFOX) improves median
overall survival by 4.4 months compared to irinotecan, bolus 5-FU and leucovorin (IFL).3
Bevacizumab received FDA approval based upon 4.7 month improvement in survival when
added to IFL.4 Cetuximab, when given alone has a median time to progression (TTP) of 1.5
months; combining this antibody with irinotecan increases median TTP to 4.1 months.5 The
progression free survival (PFS) of chemotherapy refractory patients treated with panitumumab
is 8 weeks compared to 7.3 weeks in patients treated with best supportive care alone6.
The National Comprehensive Cancer Network (NCCN) Practice Guidelines for Colorectal
Cancer recommend that patients with good tolerance for intensive chemotherapy be treated
initially with 5FU-based combination chemotherapy and bevacizumab. The guidelines suggest
additional chemotherapy and/or cetuximab or panitumumab in the second and third line
settings, ultimately exposing patients to all available classes of agents.7
With the exception of 5-FU and irinotecan (which recently came off patent), these drugs are
very expensive and the cost implications of these promising medications, are the subject of
significant debate.8-10 There are limited data in the published literature regarding the cost
effectiveness of treatments for patients with metastatic colorectal cancer. Hillner used data
from the multicenter study NCCTG 9741 to compare treatment with IFL to FOLFOX and
found that the 4.4 month median survival benefit of the FOLFOX arm was accompanied by
an incremental cost of $29,953, resulting in an incremental cost effectiveness ratio (ICER) of
$80,410 per life year gained.11 Starling examined the role of cetuximab and irinotecan
compared to best supportive care from the perspective of the United Kingdom National Health
Service and found an ICER of 42,975 pounds per life year gained. 12 To our knowledge, there
has not been a comprehensive cost effectiveness analysis that includes multiple lines of therapy.
In an effort to characterize the cost of modern treatment for metastatic colorectal cancer, we
developed a model that measures the added benefits and costs of sequential combination
regimens. Rather than performing a direct comparison of specific agents or regimens, our
model evaluates broad categories of therapies, such as antibody-containing regimens versus
non-antibody containing regimens, and treatment strategies that include one, two or three lines




We used TreeAge Pro 2006 to develop a Markov model (Figure 1) to follow the natural history
of patients treated for metastatic colorectal cancer. Patients can be treated with one, two or
three lines of therapy prior to supportive care and death. Patients are evaluated at weekly
intervals (Markov Cycles) and can either remain on therapy at stable doses, develop toxicity
or die. Patients who develop toxicity will die, continue on therapy at a dose reduction, or change
therapy.
Perspective—Third party payor.
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For this model, we used nine possible treatment strategies (Table 1). Although there are many
possible other treatment sequences, these were selected to reflect the sequential advances in
colorectal cancer treatment. Sequence A includes 5FU/LV alone followed by supportive care.
Regimens B, C, D, and E are increasingly complex regimens. F and G contain all available
regimens but use irinotecan and oxaliplatin in different orders; H and I are identical to F and
G but use combination irinotecan and cetuximab in the third line. Doses, schedules and costs
are shown in Table 2.
Costs
We based cost on average sales price (ASP) for a 75 kg patient who was 69 inches tall (BSA=1.9
m2) provided by the Centers for Medicare and Medicaid Services
(http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice accessed April 20,2008). Geeneric
irinotecan was approved in February 20, 2008; however impact of generic irinotecan was not
reflected in the Medicare payment amount until October 1, 2008.13 We included an estimated
pump rental cost for regimens containing infusional 5FU ($300 per week). We assumed no
vial wastage, and did not include supportive care medications, costs related to management of
toxicity, radiographic studies, physician visits or indirect costs
Life Expectancy
We measured overall survival, and assumed that living patients in all health states have
equivalent values. In every health state and cycle, patients face competing all-cause mortality
rates. Since the median age at diagnosis of colon cancer is approximately 70 years, we used
US life table data for a 70 year-old man in our base case analysis.
Data Sources
Estimates of rates of progression and toxicity were obtained from published results of
multicenter Phase II and randomized Phase III studies (Table 3). In addition, we included
unpublished aggregate data from NCCTG 9741 (FOLFOX vs. IFL in first line therapy). We
restricted data to peer reviewed publications and excluded abstract presentations.
Progression
We used time to progression (TTP) or progression free survival (PFS) data to estimate the
length of time patients were on treatment. When more than one source was available, we chose
the source with the larger sample size. To estimate the benefit of the addition of bevacizumab
to FOLFIRI or FOLFOX, we added 4.6 months (the increased TTP of IFL plus bevacizumab
compared to IFL alone) 4 to the TTP of these regimens.
Toxicity
We used reported rates of grade 3 (severe) or 4 (life-threatening) toxicity. We used toxicity
rates of FOLFOX and FOLFIRI alone as the toxicity rates for the respective bevacizumab-
containing regimens, which provide a conservative estimate of treatment-related toxicity. We
assumed that patients could have up to 2 toxic events before discontinuing treatment. We
assumed that the probability of having a second toxic event was 10%; we fit the model using
this estimate to general clinical outcomes consistent with clinical practice and varied this figure
in sensitivity analyses.
Calculations of Probability for Progression and Toxicity
We assumed that toxicity and progression were independent and mutually exclusive events
over the course of a one-week cycle. Progression rates were abstracted from trial results and
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converted to weekly probabilities using the declining exponential approximation of life
expectancy (DEALE).14, 15 Toxicities were converted to probabilities using the DEALE and
fractionated into fatal and non-fatal outcomes. After running the Markov analyses, expected
survivals expressed as means were transformed back to median PFS/TTP intervals.
Supportive Care
The model is designed so that patients spend approximately 24 weeks (undiscounted) on
supportive care, based on the observation that patients who received supportive care rather
than second line irinotecan had a median survival of six months.16 In addition, Starling
estimated that patients who received best supportive instead of cetuximab and irinotecan lived
5.6 months.12 We used cost of $135/day, based on Medicare reimbursement17
Incremental Cost Effectiveness Ratios (ICER)
For clarity of presentation, we present regimens A, C, G and I. These regimens were selected
because they reflect increasingly effective treatments:
Pair 1: Comparing C to A measures the survival advantage offered by modern
chemotherapy agents (irinotecan and oxaliplatin) compared to 5FU/LV alone.
Pair 2: Comparing G to C measures the survival advantage offered by the addition of
antibodies to modern chemotherapy.
Pair 3: Comparing I to G represents the survival advantage offered by the most aggressive
sequence in this model.
Sensitivity Analyses
We performed one-way sensitivity analyses in which we measured the effects of changes in
toxicity, progression, drug costs, probability of second toxicity, time on supportive care and
cost of supportive care on the overall cost effectiveness of the model. We report the ICERs of
Pairs 1, 2 and 3. We performed a separate sensitivity analysis to measure the impact of generic
irinotecan. (estimated to be approximately one third the cost of brand irinotecan).13
Monte Carlo Simulation
To measure the impact of uncertainty of all variables, we performed two dimensional sensitivity
analyses using a Monte Carlo simulation. We studied 1000 hypothetical patients as they
transitioned through the model over their beta probability distributions of toxicity and
progression. To measure the impact of lower drug prices on the cost effectiveness ratios, so
we varied the rates between 25 and 106% of ASP on a triangular distribution.
Discounting
Life expectancy and costs were discounted 3% per year.
Results
Base Case
The cost and effectiveness for each sequence is presented in Table 1. The cost effectiveness
frontier for the base case scenario is presented in Figure 2. Similar sequences that vary the
order in which irinotecan and oxaliplatin are given (F and G; H and I) have similar life
expectancies.
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Incremental Cost Effectiveness Ratios (ICERS)
ICERS for selected sequences are shown in Table 4. The ICER per discounted life year (DLY)
gained for adding the modern chemotherapy agents is approximately $100,000/DLY gained.
The benefits of adding antibody come at higher costs ($170,000/DLY). The modest additional
benefit of the most effective regimen in this model (using both cetuximab and irinotecan in the
third line setting) generate even higher costs ($240,000/DLY)
Sensitivity Analysis
The CE frontier using generic irinotecan pricing is show in figure 3; as expected, the overall
cost of treatments containing front line irinotecan are lower than those containing front line
oxaliplatin.
In addition, we performed one-way analyses on rates of several key parameters for pairs 1, 2
and 3 (Tables 5-8). The “base case” results are shaded, with lower and higher rates of each
variable on the left and right, respectively. These results showed that despite improvements in
the clinical parameters (toxicity and progression), cost, and length of supportive care, the
ICERs for the antibody containing sequences (G and I) are very high. The most significant
changes in the ICERs occurred when the parameters for first line treatment were changed.
Because we chose to focus on the pair-wise comparison of treatment strategies of lesser or
greater effectiveness, the information is best interpreted by analyzing columns, which represent
escalating effectiveness of treatment; with the exception of the analysis on second toxicity
(Table 7), the ICERs uniformly increase reading down the columns.
For example, Table 5 shows that a 50% decrease in progression rates (i.e. shorter time on first
line treatment) for first line treatment would result in increased ICERS; for the incremental
benefit of the most aggressive treatment (Pair 3) would actually be “dominated” and be more
costly and less effective. On the other hand, improving the efficacy of front therapy (150% of
base case) has the greatest impact on the ICERs, likely because the patients spend the longest
time on first line therapy. The results were only modestly sensitive to the cost of the infusion
pump, cost or time on supportive care (results not shown).
Monte Carlo Simulation (Figure 4)
The scatter plot shows that there are two distinct “bands” of treatment sequences; the steeper
slope in the right upper portion of the figure includes the regimens that incorporate antibodies.
Discussion
We found that survival increases as patients with metastatic colorectal cancer are exposed to
all available agents, but this benefit comes at high cost. This cost exceeds commonly accepted
cost-effectiveness thresholds.18 Furthermore, our estimates only include drug costs,
representing a conservative estimate of total treatment expense. Patients who are treated with
5FU/LV, oxaliplatin, and irinotecan have longer survival compared to 5FU/LV alone, at an
ICER of approximately $100,000/DLY. However, treatment with antibody-containing
regimens is associated with higher ICERs due to the relatively modest survival benefits and
high costs. These results are similar to an analysis of salvage chemotherapy in platinum-
refractory ovarian cancer, which found that second line monotherapy came at an ICER of
$57,000/DLY, but the benefits of second line doublet therapy and third line monotherapy came
at unacceptably high incremental cost.19 Whether the benefits are worth the costs clearly
depends on the stakeholder; patients with advanced cancer may perceive greater value than
healthy patients, policymakers, insurers, and physicians.8, 9
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Our goal was not to compare “competing” regimens such as FOLFOX and FOLFIRI, which
are both acceptable first line treatment strategies,20 but instead to study the impact of sequential
progress (new chemotherapy and antibodies) on the overall cost of managing metastatic
colorectal cancer. We found that similar treatment sequences (F and G or H and I) had similar
life expectancies when prices for brand irinotecan were used. This suggests that ICERs are not
affected by the sequence in which the drugs are used, but the effectiveness of the overall
treatment strategy. Our sensitivity analyses show that the ICERs are most affected by changes
in first line therapy, since this is associated with the longest PFS. This is of particular
significance as a phase III study is underway that explores the use both bevacizumab and
cetuximab in combination with chemotherapy in the front line setting. (Clinicaltrials.gov
identifier NCT00265850).
We believe that it is reasonable to use life expectancy, rather than quality adjusted life
expectancy as our measure for several reasons. Patients with life threatening diseases may
choose treatments associated with a high risk of toxicity but low potential benefit.21, 22 In
addition, using life expectancy rather than utilities results in a conservative (lower) estimate
for ICERs, since preference weights for patients with advanced cancer are generally less than
one.23
Limitations
Decision analysis models are limited by the accuracy of the probability estimates. Toxicity
estimates are based on published data from Phase III and multicenter Phase II trials, which
were inconsistently reported. We assumed that only grade 3 and 4 toxicities would prompt a
dose reduction, delay or change in therapy. However, patients may discontinue or delay
treatment for other reasons.24 In addition, the rate of toxicities in clinical trials may not
accurately reflect community practice since clinical trial patients may be more robust than an
unselected patient population. However, our sensitivity analysis show that changing the
toxicity rates (Table 6) does not significantly alter the ICER, since changes in toxicity would
also accompanied by changes in drug utilization. As shown in Table 7, only if the probability
of second toxicity is 50% in all three lines of treatment, would the ICERs drop significantly.
In our model, we assumed that bevacizumab would add 4.4 months to FOLFIRI or FOLFOX
based on its benefit seen when added to IFL.4. However, it is possible that the benefit of
bevacizumab may be less. In N016966, the magnitude of benefit of the addition of bevacizumab
to chemotherapy was shorter than expected (9.4 months vs. 8.0 months).25 The addition of
bevacizumab to FOLFIRI in BICC C resulted in a PFS of 11.2 compared to 8.3 months for
IFL, though the difference was not statistically significant.26 If our model overestimates the
benefit of the addition of bevacizumab to front-line chemotherapy, this will result in a
conservative (lower) estimate of the ICER. As our sensitivity analysis shows (Table 6), a 50%
decrease in progression in first line therapy results in higher ICERs.
This discrepancy also raises questions about the cost effectiveness of multi-drug regimens. In
contrast to the shorter PFS from the addition of bevacizumab to FOLFIRI and FOLFOX (11.2
and 9.4 months) reported in these recent clinical trials, a phase II study of 5FU/LV and
bevacizumab alone have found a relatively long median PFS of 9.2 months,27 Therefore, the
benefit of adding oxaliplatin or irinotecan to 5FU and bevacizumab needs to be further
investigated both from a clinical and cost-effectiveness standpoint.
We only included intravenous regimens in our model. Capecitabine is considered equivalent
to intravenous 5FU as a single agent for both localized and metastatic disease. In addition,
capecitabine and oxaliplatin was found to be non-inferior to FOLFOX28 and this regimen is
also included in the NCCN guidelines. Studies in the adjuvant setting have found that despite
its higher drug cost, capecitabine may be cost effective given the reduced drug administration
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costs and indirect costs (travel time, lost work).29, 30 However, since we only included drug
costs in our model capecitabine's high cost would bias the results against capecitabine
containing regimens.
We also chose to include only one EGFR inhibitor in our model. Like cetuximab, panitumumab,
is indicated as a single agent after failure of prior chemotherapy. However, it is not approved
in combination with chemotherapy. In addition, there is no role for sequential use of EGFR
inhibitors. Although there are no head to head data comparing panitumumab and cetuximab,
the median progression free survival for panitumumab as last line therapy are similar (8 weeks
vs. 1.5 months). Since cetuximab can be used as both a single agent and in combination with
chemotherapy, we chose to use this in our model. This might result in higher ICERs, since
drug costs for panitumumab are lower than cetuximab (Table 2). However, as the sensitivity
analyses for drug costs show (Table 8), decreasing the drug costs in the third line setting only
results in small changes in the ICERs, given the modest activity of these agents and short
duration of therapy for most patients who are treated in these settings. For example, when drug
costs are decreased to 25% of the base case for all three lines of treatment, ICERs decrease
significantly. However, if only 3rd line drug costs are considered, the ICERs only drop
modestly.
We also did not include the costs of managing toxicities such as diarrhea or infection, since
they should be small relative to overall drug costs. We do not believe that this would bias the
results significantly in favor of one particular sequence since patients on the most effective
sequences (F, G, H and I) are exposed to all of the available agents and thus will likely
experience similar associated side effects and management costs. In practice, treatment breaks
are now commonly employed.24 Several strategies are being explored where patients on
FOLFOX or FOLFIRI are offered scheduled periods entirely off chemotherapy or off
oxaliplatin or irinotecan.31, 32 If treatment “holidays” for select patients provide similar
survival to those patients treated continuously, the ICERs may be improved since such patients
will not be accruing comparably high treatment-related costs.
Future Directions
Although our study uses metastatic colorectal cancer as a platform for discussion, these issues
are relevant to many cancer types, where advances in translational research have led to the
introduction of new targeted therapies. The costs for palliative treatment of will likely increase
as patients are treated with sequential therapies until death or toxicity.
Given these high costs, future studies should be designed to address both dose intensity and
duration of treatment. For example, although bevacizumab was approved at 10 mg/kg every
two weeks in conjunction with FOLFOX, it is unclear if this dose is more beneficial than the
previously approved 5 mg/kg every two week dose studied in conjunction with IFL.33 In
addition, it is important to establish the role of continuing antibody therapy following failure
of first-line chemotherapy. An ongoing NCI-sponsored Intergroup Bevacizumab Continuation
Study is randomizing patients with metastatic colorectal cancer who have had progressive
disease while on FOLFOX and bevacizumab to irinotecan plus cetuximab alone or with
bevacizumab. (Clinicaltrials.gov identifier NCT00499369) It is important to identify which
patients are most likely to benefit from these treatments; recent data suggest that patients with
mutant KRAS derive no benefit from the addition of cetuximab to FOLFOX or FOLFIRI, while
patients with wild-type KRAS demonstrate improved outcomes.34, 35 Other studies have also
shown that the efficacy of panitumumab is also confined to patients with wild type K-ras.36
The cost will decrease as generics become available. At the time this article was written, the
payment for branded irinotecan was approximately 145% greater than generic versions. As our
sensitivity analyses on drug costs shows (Table 8), a 50% decrease in the cost of first line
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therapy will result in a $1200 decrease in ICER for Pair 3; the most substantial decreases occur
when all three lines of treatment occur simultaneously. However, since oxaliplatin,
bevacizumab and cetuximab, all remain under patent protection, the overall cost of treatment
will still remain very high. Nevertheless, its availability raises an important societal question.
When prices for generic irinotecan are used, the results clearly favor using regimens that
include FOLFIRI in the front line setting given the lower cost.(Figure 3) This is supported by
our finding that ICERs are most sensitivity to the changes in cost in the front line therapy,
given the longer duration of treatment. Although FOLFIRI and FOLOX are both acceptable
front line regimens, the majority of US physicians choose FOLFOX for front line treatment.
37 Although the current reimbursement system for chemotherapy does not favor the use of
generic regimens, payors may want to consider this as a mechanism for cost control in cases
where similar clinical outcomes are obtained with alternate treatments that vary widely in cost.
The potential savings to payers (including taxpayers) will need to be weighed against patients'
and physicians' preferences for side effects.
The cost of cancer care will continue to rise as new palliative treatments are introduced, and
patients incur costs as they live longer. We can be optimistic that these promising new agents
may be truly “cost effective” if they are effective in the adjuvant setting. Cost-effectiveness
assessments should be included in studies of new treatments, such that policymakers can make
more informed decisions regarding coverage, and patients and oncologists can make the most
informed decisions regarding treatment.
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Stylized Markov Model: Patients can receive up to three lines of therapy. Patients can also die
in any health state from all cause mortality. (not shown)
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Cost Effectiveness Frontier (Discounted Cost and Effectiveness) (fixed)
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CE Frontier using Generic Irinotecan (cost and effectiveness)
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Table 2
Regimens, Doses and Costs
Regimen Estimated Cost over 6 months (24 weeks)
5FU/LV 5FU 425mg/m2 and LV 20 m/gm2 daily for 5 days, every 28 days $96
Capecitabine* 1000 mg/m2 twice daily for 14 days every 21 days $11,304
FOLFOX 5FU 400 mg/m2m, LV 400 mg/mg, Oxaliplatin 85 mg/m2 then 5FU 2400m/
mg2 every 14 days
$33,270
FOLFIRI 5FU 400 mg/m2m, LV 400 mg/mg, Irinotecan 180mg/m2 then 5FU 2400m/
mg2 every 14 days
$23,529
Irinotecan Irinotecan 350m/gm2 every 21 days $30,100
Cetuximab 400mg/m2 followed by 250mg/m2 weekly $52,080
Panitumumab* 6 mg/kg every 14 days $41,457
Bevacizumab Bevacizumab 5mg/kg every 14 days $24,123
*
Not included in model
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Table 5
Progression
Pair 50% 100% 150%
First line 1 $121,784 $102,336 $95,784
2 $208,052 $170,872 $158,028
3 dominated $243,100 $164,372
Second line 1 $93,444 $102,336 $108,420
2 $175,240 $170,872 $169,156
3 $334,776 $243,100 $229,892
Third line 1 $102,336 $102,336 $102,336
2 $157,560 $170,872 $176,748
3 $217,776 $243,100 $274,404
All 1 $108,576 $102,336 $101,192
2 $194,480 $170,872 $161,876
3 dominated $243,100 $160,784
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Table 6
Toxicity
Pair 50% 100% 150%
First line 1 $101,400 $1,968 $1,995
2 $165,620 $170,872 $176,384
3 $151,736 $243,100 $974,792
Second line 1 $102,076 $102,336 $103,064
2 $171,340 $170,872 $170,560
3 $242,996 $243,100 $246,532
third line 1 $102,336 $102,336 $102,336
2 $171,392 $170,872 $170,664
3 $240,344 $243,100 $250,276
$0 $0 $0
All 1 $101,192 $102,336 $104,624
2 $166,452 $170,872 $175,760
3 $152,360 $243,100 >$ 2 million
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Table 7
Probability of Second Toxicity
Pair 0% 10% 50%
First line 1 $95,264 $107,328 $117,104
2 $150,228 $185,952 $209,196
3 $123,552 dominated dominated
Second line 1 $100,516 $103,896 $111,332
2 $171,496 $170,456 $168,740
3 $212,316 $262,964 $287,040
Third line 1 $102,336 $102,336 $102,336
2 $170,664 $171,132 $172,588
3 $227,188 $259,376 $400,972
All 1 $94,068 $109,408 $143,156
2 $150,644 $185,796 $214,552
3 $123,604 dominated $40,092

















First line 1 $56,940 $102,336 $132,652
2 $54,808 $170,872 $248,300
3 $145,652 $243,100 $308,048
Second line 1 $66,924 $102,336 $125,996
2 $173,732 $170,872 $169,000
3 $307,268 $243,100 $200,356
Third line 1 $102,336 $102,336 $102,336
2 $153,920 $170,872 $182,208
3 $101,816 $243,100 $337,272
All 1 $21,476 $102,336 $156,260
2 $40,664 $170,872 $257,712
3 $68,536 $243,100 $359,476
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